BioNTech, Pfizer join forces to develop mRNA-based flu vaccines


BioNTech, a German biotechnology company, has joined forces with US pharma giant Pfizer to develop mRNA-based flu vaccines as part of a $425 million multi-year research and development (R&D) collaboration.

As per the terms of the deal, BioNTech and Pfizer will jointly take up research and development activities for advancing mRNA-based vaccines to prevent influenza (flu).

Pfizer will be solely responsible for further clinical development and commercialization of mRNA-based flu vaccines once BioNTech completes a first in human clinical trial.

Kathrin Jansen – Senior Vice President and Head of Pfizer’s Vaccine Research and Development Unit, commenting on BioNTech collaboration with Pfizer, said: “Innovative vaccine approaches are urgently needed to provide improved protection against seasonal flu, and to respond rapidly and in quantity to pandemic influenza threats. mRNA vaccines offer a novel approach to code for any protein or multiple proteins, and the potential to manufacture higher potency flu vaccines more rapidly and at a lower cost than contemporary flu vaccines.

See also  OnPoint Community Credit Union to open 20 branches in Fred Meyer stores

“BioNTech is one of the industry leaders in mRNA technology and we are looking forward to working closely with them to help bring cutting-edge mRNA influenza vaccines to the market to improve people’s lives.”

BioNTech, Pfizer form alliance to develop mRNA-based flu vaccines

BioNTech, Pfizer form alliance to develop mRNA-based flu vaccines. Photo courtesy of BioNTech AG.

Under the terms, BioNTech will get an upfront amount of $120 million from Pfizer followed by equity and near-term research payments and up to a further $305 million in payments associated with potential development, regulatory and commercial milestones.

See also  AstraZeneca to acquire US biotech firm TeneoTwo for up to $1.27bn

Apart from that, the German biotechnology company will stand to earn up to double-digit tiered royalty payments related to global sales if the mRNA-based flu vaccine program achieves commercialization.

Commenting on BioNTech collaboration with Pfizer, Prof. Dr. Ugur Sahin – Co-Founder and CEO of BioNTech, said: “Today’s agreement with Pfizer is one of a number of steps that we are taking to rapidly build a sustainable R&D presence in infectious disease, combining our deep understanding of the immune system to treat disease with the cutting-edge technologies and significant infrastructure that we have built-up over many years to develop immunotherapy treatments.

See also  ExxonMobil amplifies chemical production at Baytown refinery with $2bn investment

“A significant presence in infectious disease supports our goal of building a global immunotherapy company that provides more effective and precise immune-mediated approaches for the prevention and treatment of serious illnesses, such as the prevention of flu and the treatment of cancer.”

For more updates on the development of the mRNA-based flu vaccines and news related to BioNTech and Pfizer, keep following

Share This